Shukra Pharmaceuticals bags Rs. 24 crore medicines supply contract from HSCC India

FDA approves Teva Pharmaceuticals' first GLP-1 obesity drug

Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market

AbbVie to acquire Gilgamesh Pharmaceuticals’ bretisilocin for $1.2 billion

SMS Pharmaceuticals receives EIR from USFDA for Central Laboratory Analytical Services

The inspection, conducted from June 23 to June 25, 2025, concluded with zero Form 483 observations

Akums Drugs and Pharmaceuticals signs framework agreement with Govt. of Zambia

This project shall be implemented through incorporation of a new joint venture company in Zambia

Glenmark Pharmaceuticals USA to launch Micafungin for injection USP, 50 mg/vial and 100 mg/vial

According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million

Senores Pharmaceuticals acquires ANDAs from Teva Pharmaceuticals USA

The acquired ANDAs represent a market opportunity of about US$ 38 million in the USA

Glenmark Pharmaceuticals reached $37.75 million settlement in antitrust litigation in US

Glenmark USA is named in multiple antitrust and consumer protection lawsuits, including class actions, consolidated in the Eastern District of Pennsylvania, U.S

Centrient Pharmaceuticals joins UNGC

Reinforcing commitment to ethical and sustainable growth

SMS Pharmaceuticals reports consolidated Q1 FY26 at Rs. 20.49 Cr

SMS Pharmaceuticals has reported total income of Rs. 196.64 crores during the period ended June 30, 2025